Press release
Human Immunodeficiency Virus Therapeutics Market Research Explores Growth Within A $19.39 Billion Opportunity
Human Immunodeficiency Virus Therapeutics Market
Human Immunodeficiency Virus Therapeutics Market Size and Growth Outlook Through 2030
The market for human immunodeficiency virus therapeutics is predicted to grow steadily, reaching a valuation of $19.4 billion by 2030. This expansion corresponds to a compound annual growth rate (CAGR) of 5.4% throughout the forecast period. Several factors contribute to this growth, including the increasing demand for long-acting HIV therapies, a stronger focus on personalized treatment plans, improved access to treatments in low- and middle-income countries, rising investments in next-generation antiretroviral drugs, and a growing emphasis on lifelong management of the disease. Key trends driving the market include a shift towards combination antiretroviral therapies, an uptick in the use of long-acting injectable treatments, prioritizing early and sustained viral suppression, broader availability of generic antiretroviral drugs, and initiatives to simplify regimens and enhance treatment adherence.
The human immunodeficiency virus therapeutics market size has grown strongly in recent years. It will grow from $14.9 billion in 2025 to $15.73 billion in 2026 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to global burden of hiv infections, widespread adoption of antiretroviral therapy, government-funded hiv treatment programs, increasing availability of generic hiv drugs, improved survival rates among hiv patients.
Download a free sample of the human immunodeficiency virus therapeutics market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23419&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR
Primary Factors Propelling Growth in the HIV Therapeutics Market
One of the main forces behind the market's expansion is the increasing adoption of long-acting HIV therapeutics, which offer greater convenience and improved patient compliance compared to daily oral medications. This shift supports better disease management and helps reduce the likelihood of viral resistance.
Additionally, the focus on personalized HIV treatment regimens ensures therapies are tailored to individual patient needs. This approach optimizes effectiveness and minimizes side effects, driving greater demand for advanced therapeutic options worldwide.
Leading Players in the Human Immunodeficiency Virus Therapeutics Market
Several key companies are at the forefront of the HIV therapeutics landscape, including well-known names such as Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., AbbVie Inc., Johnson & Johnson, Bristol Myers Squibb Company, Pfizer Inc., F Hoffmann La Roche Ltd., Sanofi SA, Novartis International AG, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Cipla Limited, Aurobindo Pharma Limited, Hetero Labs Limited, Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr Reddy's Laboratories Ltd., and Mylan N.V.
In a notable industry move, Future Pak, a US-based contract development and manufacturing organization (CDMO), acquired Theratechnologies Inc. in July 2025 for up to $254 million. This acquisition strengthens Future Pak's position in the HIV therapeutics market by bringing Theratechnologies' marketed HIV drugs like Trogarzo (ibalizumab) and Egrifta (tesamorelin) into its portfolio, while leveraging the company's experience in commercialization to fuel further growth. Theratechnologies, based in Canada, is recognized for its HIV-focused product line, especially its monoclonal antibody Trogarzo and treatment for HIV-associated lipodystrophy, Egrifta.
View the full human immunodeficiency virus therapeutics market report:
https://www.thebusinessresearchcompany.com/report/human-immunodeficiency-virus-therapeutics-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR
Emerging Trends Transforming the HIV Therapeutics Market
Industry leaders are increasingly prioritizing the development of long-acting and highly effective HIV prevention and treatment options. These innovations aim to improve patient adherence and reduce new infections by offering more convenient and less frequent dosing schedules.
For instance, in June 2025, Gilead Sciences received FDA approval for Yeztugo (lenacapavir), which stands out as the first and only twice-yearly injectable pre-exposure prophylaxis (PrEP) treatment. Supported by robust Phase 3 PURPOSE 1 and PURPOSE 2 clinical trial data, Yeztugo demonstrated remarkable efficacy, with 99.9% or more of study participants remaining HIV-negative. This long-acting injectable addresses issues such as adherence difficulties, stigma, and low awareness that have limited the broader use of PrEP, providing a promising new tool to help curb HIV transmission across diverse populations. Gilead is also expanding access through insurance partnerships, co-pay assistance, and free access programs for uninsured patients.
How the Human Immunodeficiency Virus Therapeutics Market is Categorized
This market is segmented by drug type, distribution channel, and end-user to provide a clear understanding of its structure.
1) Drug Type: Branded Drugs and Generic Drugs
2) Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
3) End-User: Hospitals and Clinics, Specialty Centers
Within branded drugs, leading products include Biktarvy, Triumeq, Genvoya, Juluca, Dovato, Isentress, and Prezista. For generics, the main drugs are Tenofovir Disoproxil Fumarate (TDF), Lamivudine, Efavirenz, Zidovudine, Nevirapine, Abacavir, and Ritonavir.
This comprehensive segmentation highlights the diverse range of treatment options and access points that contribute to the overall growth and accessibility of HIV therapeutics globally.
Expanded capabilities in our 2026 market reports:
• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Human Immunodeficiency Virus Therapeutics Market Research Explores Growth Within A $19.39 Billion Opportunity here
News-ID: 4608667 • Views: …
More Releases from The Business Research Company
Hyperlipidemia Market Research Reveals Path To $25.54 Billion By 2030
Understanding the evolving landscape of the hyperlipidemia market reveals promising opportunities driven by new therapies and growing awareness. As medical advancements continue, the sector is set for significant expansion, supported by innovative treatments and a stronger focus on preventive care. Let's explore the current market value, key players, emerging trends, and critical segments shaping this field.
Projected Market Value of the Hyperlipidemia Market by 2030
The hyperlipidemia market is anticipated…
Hepatorenal Syndrome Market Report Examines Industry Trends, Growth Drivers And …
The hepatorenal syndrome market is gaining substantial attention as advancements in treatment and diagnosis continue to evolve. With increasing focus on early intervention and innovative therapies, the industry is set to experience notable expansion over the coming years. Let's explore the market size outlook, key players driving progress, emerging trends, and the main segments shaping this field.
Forecasted Market Size and Growth in the Hepatorenal Syndrome Industry
The hepatorenal syndrome…
Hypercholesterolemia Market Demonstrates Long-Term Growth Potential At 13.8% CAG …
The hypercholesterolemia market is positioned for substantial expansion over the coming years, driven by advancements in treatment options and increasing public awareness. With breakthroughs in diagnostics and therapies, this sector is rapidly evolving, offering promising prospects for patients and healthcare providers alike. Let's explore the market size projections, key players, emerging trends, and the primary segments shaping this industry.
Projected Market Size and Growth Trajectory of the Hypercholesterolemia Market
The…
Hepatitis C Testing Market Report Examines Leading Companies And Growth Opportun …
Understanding the upcoming growth and dynamics of the hepatitis C testing market reveals significant opportunities driven by technological advances and increasing healthcare focus. This overview explores the market size projections, key players, emerging trends, and detailed segmentations shaping the future of hepatitis C diagnostics globally.
Forecasted Growth and Market Size for Hepatitis C Testing by 2030
The hepatitis C testing market is anticipated to experience substantial expansion over the next…
More Releases for HIV
HIV Drugs Market - Defeating HIV Together: Advancing Treatment Options for a Bri …
Newark, New Castle, USA: The "HIV Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
HIV Drugs Market: https://www.growthplusreports.com/report/hiv-drugs-market/7792
This latest report researches the industry structure, sales, revenue,…
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of…
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication…
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments
Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV…
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Introduction to Human Immunodeficiency Virus (HIV) Vaccines
1.1 Overview
1.2 Antiquity of HIV Vaccine
Need for the Development of HIV Vaccine
Primer of HIV inside the Body
3.1 Inclusion of HIV Virus into the System
3.2 Interaction of HIV with Host
3.3 Eradication of HIV Virus
HIV Vaccine Development Process
4.1 Introduction
…
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways…
